CL2008003939A1 - Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00). - Google Patents

Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00).

Info

Publication number
CL2008003939A1
CL2008003939A1 CL2008003939A CL2008003939A CL2008003939A1 CL 2008003939 A1 CL2008003939 A1 CL 2008003939A1 CL 2008003939 A CL2008003939 A CL 2008003939A CL 2008003939 A CL2008003939 A CL 2008003939A CL 2008003939 A1 CL2008003939 A1 CL 2008003939A1
Authority
CL
Chile
Prior art keywords
escitalopram
treatment
pharmaceutically acceptable
acceptable salt
prepare
Prior art date
Application number
CL2008003939A
Other languages
English (en)
Inventor
Connie Sanchez
Sandra Hogg
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003939(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2008003939A1 publication Critical patent/CL2008003939A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Uso de escitalopram o una sal farmacéuticamente aceptable para el tratamiento de la ansiedad social (divisional de la sol. 1799-00).
CL2008003939A 1999-07-08 2008-12-30 Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00). CL2008003939A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA199900991 1999-07-08

Publications (1)

Publication Number Publication Date
CL2008003939A1 true CL2008003939A1 (es) 2009-06-05

Family

ID=8099796

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2008003939A CL2008003939A1 (es) 1999-07-08 2008-12-30 Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00).
CL2008003938A CL2008003938A1 (es) 1999-07-08 2008-12-30 Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
CL2008003941A CL2008003941A1 (es) 1999-07-08 2008-12-30 Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden compulsivo obsesivo.

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2008003938A CL2008003938A1 (es) 1999-07-08 2008-12-30 Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
CL2008003941A CL2008003941A1 (es) 1999-07-08 2008-12-30 Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden compulsivo obsesivo.

Country Status (38)

Country Link
US (6) US7271194B2 (es)
EP (4) EP1440689A3 (es)
JP (1) JP4773011B2 (es)
KR (1) KR100604176B1 (es)
CN (1) CN1198610C (es)
AR (1) AR021155A1 (es)
AT (1) ATE339955T1 (es)
AU (6) AU782514B2 (es)
BG (4) BG110467A (es)
BR (1) BR0011578A (es)
CA (4) CA2687392A1 (es)
CL (3) CL2008003939A1 (es)
CO (1) CO5190674A1 (es)
CY (1) CY1105806T1 (es)
CZ (1) CZ200270A3 (es)
DE (1) DE60030861T2 (es)
DK (1) DK1200081T3 (es)
EA (1) EA006555B1 (es)
ES (1) ES2272298T3 (es)
HK (1) HK1048069B (es)
HR (1) HRP20010820A2 (es)
HU (1) HUP0201791A3 (es)
IL (5) IL146131A0 (es)
IS (1) IS6137A (es)
ME (2) ME00032B (es)
MX (1) MXPA01011626A (es)
MY (1) MY143278A (es)
NO (4) NO329021B1 (es)
PL (1) PL352030A1 (es)
PT (1) PT1200081E (es)
SI (1) SI1200081T1 (es)
SK (1) SK82002A3 (es)
TR (4) TR200402276T2 (es)
TW (1) TWI232101B (es)
UA (1) UA77645C2 (es)
WO (1) WO2001003694A1 (es)
YU (1) YU78701A (es)
ZA (1) ZA200108856B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
DE60110914T2 (de) * 2000-07-21 2005-10-27 H. Lundbeck A/S, Valby Verbindungen und ihre verwendung als hemmer des glycintransports
KR20040030609A (ko) * 2001-05-01 2004-04-09 하. 룬트벡 아크티에 셀스카브 경상이성체성 순수 에스시탈로프람의 용도
ES2280892T3 (es) 2001-07-31 2007-09-16 H. Lundbeck A/S Composicion cristalina que contiene escitalopram.
AU2003237524A1 (en) * 2002-07-08 2004-01-23 University Of Florida Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders
RS51092B (sr) * 2002-12-23 2010-10-31 H. Lundbeck A/S. Escitalopram bromhidrat i postupak za njegovo pripremanje
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
US20050154052A1 (en) * 2003-03-24 2005-07-14 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
PL1708790T3 (pl) * 2003-12-02 2010-10-29 Pharmaneuroboost N V Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1954257A4 (en) 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (es) 1965-03-18
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4439545A (en) 1981-11-19 1984-03-27 Societe D "Expansion Scientifique "Expansia" Acrylic copolymers of N-acryloylpolymethyleneimines or N-acryloyldialkylamides, N,N'-acryloyldiaminoalcanes and N-acryloylaminoacids (or esters) their preparation and use as cation exchangers
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
DK213290D0 (da) * 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
AU1919592A (en) 1991-04-16 1992-11-17 National Institutes Of Health Method of treating trichotillomania and onychophagia
DK0612242T3 (da) 1991-11-15 2003-10-20 Sepracor Inc Anvendelse af ren S(+)-isomer af fluoxetin til fremstilling af et medikament mod migræne
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1996024353A1 (en) * 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) 1995-04-27 1995-04-27 Astra Ab A new combination
EP0759299B1 (en) 1995-08-16 2000-04-26 Eli Lilly And Company Potentiation of serotonin response
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703379D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
AU738359B2 (en) * 1997-11-11 2001-09-13 H. Lundbeck A/S Method for the preparation of citalopram
PT957099E (pt) * 1998-04-15 2003-02-28 Pfizer Prod Inc Carboxamidas heterociclicas
CA2334897A1 (en) * 1998-06-30 2000-01-06 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
DE69935331T2 (de) 1998-07-13 2007-10-31 NPS Pharmaceuticals, Inc., Salt Lake City Verfahren und verbindungen zur behandlung der depression
JP2002520353A (ja) 1998-07-16 2002-07-09 マサチューセッツ インスティテュート オブ テクノロジー ストレスの処置のための組成物
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SE9803157D0 (sv) 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
HU228576B1 (en) * 1998-10-20 2013-04-29 Lundbeck & Co As H Method for the preparation of citalopram
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
TR200102957T2 (tr) * 1999-04-14 2004-12-21 H. Lundbeck A/S Sitalopram hazırlanması için metod.
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
AU2001255654B2 (en) 2000-04-24 2005-09-22 Aryx Therapeutics Materials and methods for the treatment of depression
JP2002361405A (ja) * 2000-09-25 2002-12-18 Showa Denko Kk 熱交換器の製造方法
KR20040030609A (ko) * 2001-05-01 2004-04-09 하. 룬트벡 아크티에 셀스카브 경상이성체성 순수 에스시탈로프람의 용도

Also Published As

Publication number Publication date
DK1200081T3 (da) 2006-12-27
DE60030861T2 (de) 2007-05-03
IS6137A (is) 2001-10-30
UA77645C2 (en) 2007-01-15
AU2005202685A1 (en) 2005-07-14
US20040029958A1 (en) 2004-02-12
EP1440690A2 (en) 2004-07-28
IL170192A (en) 2010-04-29
NO20100333L (no) 2002-01-07
AU2005202684A1 (en) 2005-07-14
EP1440691A2 (en) 2004-07-28
WO2001003694A1 (en) 2001-01-18
HRP20010820A2 (en) 2003-08-31
US20040029957A1 (en) 2004-02-12
CA2687392A1 (en) 2001-01-18
US20050101665A1 (en) 2005-05-12
ZA200108856B (en) 2002-12-24
ATE339955T1 (de) 2006-10-15
US7265151B2 (en) 2007-09-04
KR100604176B1 (ko) 2006-07-25
CA2373757A1 (en) 2001-01-18
IL170193A (en) 2010-04-29
MY143278A (en) 2011-04-15
TR200200014T2 (tr) 2002-05-21
TR200402276T2 (tr) 2005-01-24
SK82002A3 (en) 2002-07-02
EP1440691A3 (en) 2004-08-25
HK1048069B (zh) 2005-12-16
AR021155A1 (es) 2002-06-12
JP2003504332A (ja) 2003-02-04
TR200402277T2 (tr) 2005-01-24
BR0011578A (pt) 2002-03-26
EP1440689A2 (en) 2004-07-28
EA200200137A1 (ru) 2002-06-27
BG110468A (en) 2010-01-29
AU5806100A (en) 2001-01-30
CO5190674A1 (es) 2002-08-29
EP1200081B1 (en) 2006-09-20
HUP0201791A2 (en) 2002-10-28
NO20100334L (no) 2002-01-07
HUP0201791A3 (en) 2005-02-28
AU2005202686A1 (en) 2005-07-14
ES2272298T3 (es) 2007-05-01
EA006555B1 (ru) 2006-02-24
AU2005202685B2 (en) 2009-01-15
EP1200081A1 (en) 2002-05-02
JP4773011B2 (ja) 2011-09-14
US20070276035A1 (en) 2007-11-29
CA2687394A1 (en) 2001-01-18
AU2008264188A1 (en) 2009-05-07
CL2008003941A1 (es) 2009-05-22
US20040029956A1 (en) 2004-02-12
US20020086899A1 (en) 2002-07-04
YU78701A (sh) 2004-03-12
CZ200270A3 (cs) 2002-04-17
EP1440690A3 (en) 2004-08-18
DE60030861D1 (de) 2006-11-02
NO20100335L (no) 2002-01-07
AU782514B2 (en) 2005-08-04
MXPA01011626A (es) 2002-06-04
CN1198610C (zh) 2005-04-27
HK1048069A1 (en) 2003-03-21
US6960613B2 (en) 2005-11-01
PL352030A1 (en) 2003-07-28
BG110466A (en) 2010-01-29
IL170194A (en) 2010-05-31
MEP2508A (xx) 2010-02-10
TR200402275T2 (tr) 2005-03-21
AU2005202684B2 (en) 2009-01-15
AU2005202686B2 (en) 2009-01-15
NO20020062D0 (no) 2002-01-07
TWI232101B (en) 2005-05-11
BG106279A (bg) 2002-08-30
AU2008264182A1 (en) 2009-01-29
EP1440689A3 (en) 2004-08-25
CN1360501A (zh) 2002-07-24
BG110467A (en) 2010-01-29
PT1200081E (pt) 2007-01-31
CA2687396A1 (en) 2001-01-18
CY1105806T1 (el) 2011-02-02
KR20020015346A (ko) 2002-02-27
IL146131A (en) 2007-02-11
ME00032B (me) 2010-02-10
NO329021B1 (no) 2010-07-26
NO20020062L (no) 2002-01-07
SI1200081T1 (sl) 2007-02-28
CA2373757C (en) 2010-01-05
US7271194B2 (en) 2007-09-18
IL146131A0 (en) 2002-07-25
CL2008003938A1 (es) 2009-05-22

Similar Documents

Publication Publication Date Title
CL2008003939A1 (es) Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00).
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
PA8514401A1 (es) Nuevos derivados de piperazina
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
SE8804629D0 (sv) New therapeutically active compounds
AR025883A1 (es) Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos
PE20010710A1 (es) Tratamiento de desordenes del sueno por medio del uso de desloratadina
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
NO20023551D0 (no) Ibuprofen-inneholdende aktivt middel-preparat
ITMI992107A0 (it) Uso del baclofen nel trattamento dell'astinenza da etanolo
IT1318667B1 (it) Medicamento antinfiammatorio.
PE20011080A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
AR035600A1 (es) Uso de agonistas selectivos del receptor de dopamina d4 en la fabricacion de medicamentos para tratar la disfuncion sexual
TR199900662T2 (xx) 1-Hidroksi-2-piridonlar�n seborik dermatit tedavisi amac�yla kullan�m�
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
ITRM950273A0 (it) Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni farmaceutiche.
NO20025461L (no) Nye formuleringer av <alfa>-(2,4-disulfofenyl)-N-tert- butylnitron
SE0000303D0 (sv) Novel compounds
YU87501A (sh) Farmaceutski kompleksi
RU99127647A (ru) Средство для лечения сексуальных дисфункций у мужчин
PT100284A (pt) Anti-helmintico de benzimidazol para uso no fabrico de um medicamento para o tratamento de infeccao microsporideos